作者:Scott A. Sadler、Hazmi Tajuddin、Ibraheem A. I. Mkhalid、Andrei S. Batsanov、David Albesa-Jove、Man Sing Cheung、Aoife C. Maxwell、Lena Shukla、Bryan Roberts、David C. Blakemore、Zhenyang Lin、Todd B. Marder、Patrick G. Steel
DOI:10.1039/c4ob01565g
日期:——
The iridium-catalysed CâH borylation is a valuable and attractive method for the preparation of aryl and heteroaryl boronates. However, application of this methodology for the preparation of pyridyl and related azinyl boronates can be challenged by low reactivity and propensity for rapid protodeborylation, particularly for a boronate ester ortho to the azinyl nitrogen. Competition experiments have revealed that the low reactivity is due to inhibition of the active catalyst through coordination of the azinyl nitrogen lone pair at the vacant site on the iridium. This effect can be overcome through the incorporation of a substituent at C-2. Moreover, when this is sufficiently electron-withdrawing protodeborylation is sufficiently slowed to permit isolation and purification of the C-6 boronate ester. Following functionalization, reduction of the directing C-2 substituent provides the product arising from formal ortho borylation of an unhindered pyridine ring.
PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
申请人:Siddiqui M. Arshad
公开号:US20120322791A1
公开(公告)日:2012-12-20
The present invention provides Pyrazolopyrimidine Compounds of Formula (I):
wherein L, T, Z, U, V, W, R
3
, R
6
, R
7
, R
8
, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.
Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
申请人:Siddiqui M. Arshad
公开号:US09227971B2
公开(公告)日:2016-01-05
The present invention provides Pyrazolopyrimidine Compounds of Formula (I):
wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.